Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Synthetic Semaglutide vs Wegovy
A 24-week Indian phase 3 trial found Sun Pharma's synthetic semaglutide non-inferior to Wegovy for percentage weight change.
Tirzepatide and Cardiovascular Outcomes
A 2026 meta-analysis found no significant MACE difference versus GLP-1 drugs, with high heterogeneity and mostly observational evidence.
Tirzepatide in Type 1 Diabetes
A matched UK cohort linked tirzepatide use to lower weight, HbA1c and insulin needs in type 1 diabetes, but it was not randomized.
GLP-1 Drugs and Aesthetic Surgery
A 2026 narrative review maps aesthetic-surgery concerns after GLP-1-related weight loss but reports no new trial or proven drug-specific effect.
GLP-1 Obesity Guide for Clinicians
A 2026 practical guide organizes obesity prescribing decisions, but it is not a new trial and does not establish a semaglutide-tirzepatide winner.
Semaglutide in Animal HFpEF Models
Rat and minipig HFpEF models showed cardiac and liver changes without substantial weight loss, but they cannot establish human efficacy.
Semaglutide for MASH: MENA Review
A MENA expert panel interprets semaglutide and resmetirom evidence for MASH, with access and regional data gaps central to adoption.
Semaglutide Missed-Dose Evidence Gap
Two 2026 letters discuss missed oral semaglutide doses, but inaccessible text limits what can be verified beyond the current product label.
Semaglutide and Gallbladder Events
A pooled STEP analysis found more gallbladder events with semaglutide 2.4 mg than placebo, but the absolute event rate remained low.
Semaglutide and Wernicke Encephalopathy
A 2026 review found six published cases of Wernicke encephalopathy after semaglutide use for obesity, but it cannot estimate incidence or prove causation.
Sequential GLP-1/GIP Mouse Study
An engineered GLP-1/GIP molecule led its mouse-study comparisons, but the preclinical result cannot predict human weight loss or safety.
SURPASS-EARLY Tirzepatide Results
SURPASS-EARLY found larger two-year HbA1c and weight reductions with tirzepatide than flexible conventional care in early type 2 diabetes.